Somerset Indus Capital Partners Raises USD 288 Million for Fund III, Exceeding Target
Somerset Indus Capital Partners has announced the final close of its third fund, Fund III, at approximately USD 288 million, surpassing its initial target of USD 250 million. The oversubscribed fund highlights strong investor confidence in Somerset’s healthcare-focused, impact-driven investment strategy.
Fund III has attracted robust participation from global institutional investors, including Development Finance Institutions (DFIs), global investment firms, domestic financial institutions, insurance companies, funds of funds, family offices, and impact investors across Europe, the United States, and Southeast Asia. The high re-up rate from existing Limited Partners (LPs), alongside commitments from new marquee investors, reflects continued support for Somerset’s “Capital for Change” philosophy.
With Fund III, Somerset aims to address healthcare access gaps across India’s “missing middle,” focusing on Tier II and Tier III markets. The fund will invest in scalable businesses providing affordable and accessible quality healthcare across delivery services, pharmaceuticals, medical devices, diagnostics, and allied sectors.
“The successful fund raise is a strong endorsement of our strategy and execution capabilities. We are grateful for the continued trust of our Limited Partners, who share our conviction that impact and financial performance can be mutually reinforcing,” said Avinash Kenkare, Partner, Somerset Indus Capital Partners.
“India’s healthcare ecosystem is undergoing a structural transformation beyond the metros. Fund III enables us to deepen our presence in underserved markets and partner with entrepreneurs building scalable healthcare platforms,” added Mayur Sirdesai, Partner.
Somerset typically invests between USD 15 million and USD 40 million per portfolio company. Through co-investment syndication with its strong LP network, the firm also participates in larger transactions ranging from USD 60 million to USD 80 million. Its investment focus includes preventive care, OPD-linked insurance, healthcare financing, MedTech innovation, and diagnostics aimed at improving accessibility beyond metro markets.
Fund III has already made three investments: Cyrix Healthcare (MedTech services), Printmann Offset (pharma packaging), and NU Hospitals (a nephrology and urology-focused single-specialty chain), all of which are demonstrating strong early performance. Somerset’s earlier funds have also delivered solid results, with Fund I generating approximately 4.0x DPI, and Fund II achieving its first exit at around 4x MOIC in 2025.
With the successful fund raise of Fund III, Somerset reinforces its position as a leading healthcare-focused private equity firm in India, continuing to align commercial success with meaningful social impact.
